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1. INTRODUCTION 
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1.1. Definition 
 
 Macular edema (ME) describes the abnormal accumulation of fluid in the central 
portion of the retina around the fovea. The increase in retinal volume leads to inflammatory 
reparative response and distortion of the vision. Macular edema is encountered in various eye 
conditions (uveitis, trauma, intraocular surgery, vascular retinopathies, vitreoretinal adhesions, 
hereditary dystrophies, diabetes, and age-related macular degeneration) and it is defined as a 
nonspecific sign (1). 
The process of fluid accumulation is most commonly linked to an alteration of the 
blood-retinal barrier (BRB). For this reason, the highly selective barrier do not carry out its 
primary role of maintaining an adequate environment for the neural tissue (2, 3). 
Characteristically, the expansion of the fluid in the macula begins in the outer plexiform 
layer and extend towards the inner nuclear and inner plexiform layers of the retina (1, 4). 
For that matter, different clinical method or imaging techniques have been used, with 
more or less success, in order to diagnose macular edema: direct and indirect ophthalmoscopy; 
fluorescein angiography; optical coherence tomography. 
 
1.2. Pathogenesis 
 
The process of fluid accumulation is most commonly linked to an alteration of the 
blood-retinal barrier (BRB) (1).  
The BRB is composed of a double barrier: an inner blood retinal barrier (iBRB) and 
outer blood retinal barrier (oBRB). Similar to the blood brain barrier (BBB), the iBRB is 
designed as tight junctions surrounding the retinal capillary endothelial cells and preventing 
arbitrary solutes diffusion. Similarly, the oBRB is formed of tight junctions between retinal 
pigment epithelial (RPE) cells. The BRB architecture provides the adequate environment for 
the retinal cells through the exchange of ions, water, proteins and sugars, and preserves the 
neural tissue from inflammatory reactions (2, 3, 5). 
Characteristically, the expansion of the fluid in the macula begins in the outer plexiform 
layer and extend towards the inner nuclear and inner plexiform layers of the retina. In the case 
of overexpansion of the macula, the increase in fluid content can reach the internal limiting 
membrane and cause a rupture of the retina, creating macular holes. The origin of the edema 
build-up may be intracellular, extracellular or both (1, 4). 
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Intracellular fluid accumulation, secondarily to a disruptive event spearing the BRB, 
results of an alteration of the ionic osmotic gradient between the retinal cells. This phenomenon 
is called cytotoxic edema and may be the consequence of a trauma or non-traumatic conditions 
(e.g., ischemia and toxic cell damage). In contrast, the increase in extracellular volume is 
caused by the failure of the iBRB or oBRB. Inflammatory cells, described as locally mediated 
cytokines, influence directly and indirectly the permeability of the BRB tight junctions (Figure 
1) (1, 4).  
 
Figure 1. Schematic presentation of the inner and outer BRBs and their relative location. ECF 
= Extracellular fluid (1) 
 
 Macular edema formation is governed by five important elements the Starling’s law is 
based on: the BRB permeability; the capillary hydrostatic pressure; the tissue hydrostatic 
pressure; the tissue osmotic pressure; and the osmotic pressure (4). 
The BRB permeability increases in the case of direct damage to retinal endothelial cells and/or 
retinal pigment epithelial cells. Moreover, any changes in the homeostasis between hydrostatic 
and oncotic pressure gradients across the BRB leads to increase in the volume of the edema (2, 
4). 
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Nevertheless, other structural barriers are present in the retina and play a no less 
important role in the prevention of macular edema (4). 
The inner limiting membrane (ILM), boundary in between the retina and the vitreous 
body, has not the necessary properties to prevent proteins and fluid from passing across this 
barrier (Figure 2) (4, 6). At this level, the intraocular passive pressure propel water into the 
retina. On the choroidal side, by the effect of osmotic pressure, the water is dragged out 
passively (4, 7).  
On the other hand, the external limiting membrane (ELM) is situated at the bases of the 
rods and cones, and is composed of zonulae adherents (Figure 2). The later, are not consider as 
dense and compact as the BRB that are, as previously mentioned, tight junctions. For this 
reason, the ELM selectively restrict large molecules movement (e.g. albumin and other 
proteins) and, as a result of this increase in oncotic pressure, keep the water into the retina. In 
consequence, the active transport of water, across the RPE, is required in order to keep the 
neural tissue free and dry of proteins and fluid (4). 
 
 
Figure 2. Layers of the retina. Light impinging on the retina comes from the top of the figure 
and passes through all the superficial layers to reach the photoreceptor rods and cones (8) 
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Consequently, the active transport at the RPE plays a protective role against fluid 
accumulation. On the contrary, in the case of retinal alteration, this compensatory mechanism 
is not properly maintained and the build-up of fluid is more pronounced in the area of protein 
aggregation, as the ELM limit the proteins diffusion (4).  
 
1.3. Diagnostic methods 
 
 Macular edema assessment is of upmost concern. As described by Staurenghi et al. (9), 
a broad range of parameters needs to be taken into account when evaluating macular edema: 
“extent of the macular edema (i.e., the area that shows increased retinal thickness); distribution 
of the edema in the macular area (i.e., focal versus diffuse macular edema); central fovea 
involvement (central area 500 µm); fluorescein leakage (evidence of alteration of BRB or ‘open 
barrier’) and intraretinal cysts; signs of ischemia (broken perifoveolar capillary arcade and/or 
areas of capillary closure); presence or absence of vitreous traction; increase in retinal thickness 
and cysts in the retina (inner or outer), and chronicity of the edema (i.e., time elapsed since 
first diagnosis and response to therapy).”. 
For that matter, different clinical method or imaging techniques have been used in order 
to diagnose macular edema. 
In the first place, direct and indirect ophthalmoscopy have been useful in determining 
the fluctuation of volume in the retina. Nevertheless, slit lamp lack reproducible measurement 
of the macular thickness variation and are based on ophthalmologist’s skills to recognize 
macular changes and anatomic details (Figure 3) (1, 9, 10). 
           
Figure 3. Postoperative fundus examination  Figure 4. Postoperative FA. Arrow = 
photo. Arrow = CME (9)    CME (9) 
 
 
6 
Therefore, fluorescein angiography (FA) has become the gold standard imaging method 
to analyse retinal capillary bed and choroidal anatomy, and to recognize breakdown in the BRB 
causing macular edema (i.e. fluorescein leakage) (Figure 4) (9, 11). Accordingly, FA may help 
to diagnose the aetiology of the macular edema: in case of DR, microaneurysms leakage are 
common; whereas in the case of RVO, vascular branches leakage running horizontally are 
identified.  Nonetheless, the technique lack two-dimensional depth perspective to allow the 
visualization of all retinal capillary layers and, as a matter of fact, exclude the observation of 
deeper vascular network (9, 12-14). 
All things considered, optical coherence tomography (OCT) has the advantage to allow 
non-invasive, in vivo visualization of the retina in two- or three-dimensional space. As a result, 
OCT gives the best images, thanks to cross-sectional images through the macula, for the 
identification of ME, its evolution and response to treatment in time (Figure 5) (1, 9).  
 
 
         
Figure 5. Macular edema on OCT. Arrow = CME.  
 
1.4. Treatment modalities 
 
 The pathophysiologies leading to macular edema are as varied and diverse as the 
number of diseases causing it: intraocular inflammation, ocular retinopathies, intraocular 
surgery, and other diseases. For this reason, a good understanding of the different 
pathophysiological mechanisms is essential in order to design the right treatment for macular 
edema. 
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 Macular edema is mainly the result of systemic and ocular diseases. This way, macular 
edema caused by systemic factors (e.g. hypertension, diabetes mellitus, hyperlipidaemia or 
inflammatory diseases) is best managed by preventing and treating of those risks. 
On the other hand, macular edema caused by ocular conditions are more commonly the 
consequence of an increase in permeability (i.e. inflammation) or a breakdown in the BRB. 
Therefore, drugs have been implemented to act at this level of the retina, such as: nonsteroidal 
anti-inflammatory drugs (NSAIDs), corticosteroids, carbonic anhydrase inhibitors (CAI), and 
anti-vascular endothelial growth factor agents (anti-VEGF).  
In the same way as medical care, successful surgical therapy of macular edema is based 
on good understanding of the cellular and biochemical mechanisms that the surgery triggers. 
Accordingly, Wolfensberger (15) considers pars plana vitrectomy and peeling internal limiting 
membrane success dependent on: the release of vitreomacular traction, good oxygenation of 
the inner retina, removal of excessive growth factors from the posterior hyaloid. 
 
1.5. Diseases-related macular edema   
 
Macular edema is a frequent end-result of multiple pathological insult such as diabetes, 
intraocular surgery (i.e. cataract extraction), intraocular inflammation, trauma and vascular 
retinopathies (1, 16). 
 
 1.5.1. Macular edema and retinal vascular disease 
  1.5.1.1. Diabetic macular edema 
 Diabetic retinopathy (DR) is considered as an ophthalmic complication damaging the 
neurovascular arrangement of the retina in diabetic patients. DR is the leading cause of new 
blindness and loss of vision in the world (17, 18). The later, may be directly caused by diabetic 
macular edema (DME), a severe consequence of DR, or by an abnormal retinal blood vessel 
growth (19). 
  Various risk factors have been identified for DR and DME, such as: systemic (20, 21) 
(e.g. diabetes severity and duration, hypertension, insulin resistance and deficiency, 
hyperlipidaemia, and hypothyroidism), lifestyle (e.g. obesity (22) and alcohol consumption 
(23)), inherited traits (24, 25) and specific periods of life (e.g. puberty (26, 27) and pregnancy 
(28)) (17, 29). 
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The way the DME develops depend on multiple factors but occurs more often 
proportionally with diabetes duration and DR severity. BRB breakdown, and consequently 
intra-retinal fluid build-up, is the most common event that leads to DME initiation (30, 31). 
Diabetes macular edema is the leading cause of vision loss in patients affected by diabetes 
mellitus and occurs in approximately 14% of these patients (30, 32). The condition is seen in 
both type of diabetes: type 1 and type 2. Ding et al. (18) observed DME prevalence ranging 
from 3% among participants within 10 years of diabetes to 20 % in those with 20 or more years 
of disease, without differences in between men and women. Nevertheless, the prevalence 
estimates are highest among African Americans and lowest among Asians. Klein et al. (33), in 
the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), found that about 20% 
diabetes type 1 and 14-25 % of diabetes type 2, depending on insulin use or not, ended-up with 
DME formation over a 10 year follow-up period (18, 29).  
Clinically significant macular edema (CSME) has been classified by the Early 
Treatment of Diabetic Retinopathy Study (ETDRS) and defined as retinal thickening of the 
center of the macula and its adjacent area (within 500 µm) with increase propensity for visual 
impairment (30, 32, 34). Ocular symptoms of DME patients are related to CSME extend and 
range from asymptomatic or slight blurry vision to total blindness if not treated (35). The 
patients very seldomly complain of partial loss of vision (e.g. scotomas) when the center of the 
macula is speared. Furthermore, it is not uncommon to draw the same conclusion if the macular 
thickening at its center is recent (36). The loss of vision is progressive, weeks to months, and 
can manifests as: metamorphopsia, faded colour vision that is more pronounced in bright 
sunlight, difficult adaptation of the vision in the darkness, and commonly, oscillation of the 
vision throughout the day or from one day to another  (30, 36-38). 
Fundoscopy use in patients affected by diabetic retinopathy is a convenient tool to 
identify DME as diffuse or localized thickened and depends on how severe the retinopathy is.  
On the other hand, FA grants the differentiation of focal and diffuse edemas leakage (9).  
Kim et al. (39) described 5 morphological models of macular edema on OCT: diffuse retinal 
thickening, cystoid macular edema (CME), posterior hyaloidal traction, serous retinal 
detachment and tractional retinal detachment with posterior hyaloidal traction. 
The management of diabetic macular edema is first dedicated to control the systemic 
risk factors mentioned above (hyperglycemia, hypertension and hyperlipidemia).  
New noninvasive treatment methods use intravitreal administration to treat DME: steroids and 
anti-VEGF drugs (e.g. ranibizumab).  
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Laser photocoagulation have been used for the treatment of DME with the aim of more 
stabilizing visual acuity than improving the vision.  
At last, vitrectomy is recommended in the case of DME with associated traction (30).  
 DME evolution is a slow, fluctuating process and when left untreated, the long-term 
prognosis is poor (30).  
 
  1.5.1.2. Retinal vein occlusions 
 Another frequently encountered retinal vascular vision loss causing disease usually 
associated with macular edema is retinal vein occlusions (RVO). As its name implies, RVO 
represent a blockage in the venous blood flow draining the retina and is affected by different 
risk factors, among which the most frequent are hypertension, diabetes, increasing age and 
glaucoma. Therefore, the obstruction produces an increase of the venous blood pressure and 
consequently homeostatic changes: swelling of the veins; hemorrhages within the retina; 
intraretinal extravasation of fluid (i.e. macular edema); and finally macular ischemia (16, 40-
48).  
RVO are classified according to the level at which the blockage is present. For this 
reason, RVO are referred such as: central retinal vein occlusion (CRVO) at the beginning of 
the optic nerve; hemiretinal vein occlusion (HRVO) at the main bifurcation of the vein; and 
branch retinal vein occlusion (BRVO) at further embranchment (40, 41). 
 RVO represent the second most common cause of blindness du to vascular impairment, 
after DR. RVO’s prevalence and incidence vary in accordance with its classification, BRVO 
being more common than CRVO. BRVO prevalence in the world among men and women 
represent 0.4% and CRVO prevalence approximately 0.08%. The cumulative rate for both 
BRVO and CRVO at 15 years display the same pattern (1.8% and 0.5% respectively) (40, 41).  
 Clinical manifestations of RVO range from mild visual field abnormalities, if the 
severity is mild and the macula is speared, to loss of visual acuity. The latter is caused by retinal 
hemorrhages, optic nerve edema and other conditions. It is interesting to point out that the 
quantity of macular edema in RVO’s patients changes throughout the day (low in the morning 
and high in the evening) (40, 41). 
 Conventional fundoscopy is an important primary diagnostic tool for the diagnosis and 
prognosis of RVO. Indeed, this technique allows differentiation of RVO into CRVO and 
BRVO, and also into ischemic (non-perfused) and non-ischemic (perfused) RVO. 
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Just as important, slit lamp biomicroscopy is obligatory for all patients affected by RVO as it 
enables the observation of iris neovascularization (i.e. blood vessels on the anterior surface of 
the iris in response to retinal ischemia). 
As mentioned above, FA is the gold standard diagnostic procedure for the diagnosis 
and prognosis of RVO. Since it allows direct qualitative observation and localization of large 
retinal vessels and retinal capillary bed, and differentiation between nonperfused and perfused 
types. For all those reasons, FA is considered a successful method for macular edema diagnosis 
and follow-up. OCT is as well frequently used, in the course of RVO, to determine retinal 
thickness (i.e. the amount of fluid in macular edema and its localization), and any modifications 
in retinal arrangement (40).  
In the Central Retinal Vein Occlusion, associations have been proven in between RVO, 
arterial hypertension and glaucoma. However, RVO risk factors management remains a 
debatable concern as no conclusive studies present decrease of intraocular pressure in 
glaucoma or improved hypertension control as visually favourable for patient affected by RVO. 
Laser photocoagulation has been shown to have beneficial gain on visual acuity for: CRVO 
patients presenting neovascularization on examination and BRVO patients with associated 
macular edema (40). 
Intraocular injections of steroids or anti-VEGF drugs seems to have a fast and positive 
action on CRVO but last for a short period (40).  
On the other hand, surgical treatment (i.e. vitrectomy) of RVO has a long-lasting effect. 
It seems that the combination of intravitreal injection of steroids and vitrectomy should allow 
quick and durable effect (40). 
 
 1.5.2. Macular edema and uveitis   
 Uveitis is an inflammation of the uveal tract and, secondarily to macular edema, can 
commonly lead to permanent visual loss (49).   
As described above (cf. 1.2. Pathogenesis), homeostasis prevails in retinal layers thanks 
to the compensatory mechanisms. However, in the case of inflammation (acute or chronic), 
triggered by traumatic, immune or infectious mechanisms, the equilibrium is disturbed and it 
results in uveitic macular edema (UME). The latter, affects 20-30% of patients with uveitis and 
60% or higher when uveitis lasts for more than a year. UME is the most common cause of 
vision loss in patient affected by uveitis. It is interesting to note that UME tends to happen in 
younger population (30-50 years old) (50). 
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Uveitis symptoms are based on the duration of the disease. Therefore, in acute 
condition, patients can complain of pain, redness, photophobia, blurred vision, lacrimation; in 
chronic condition, they mainly complain of blurred vision and mild redness (51). Importantly, 
UME particularly affects vision-related quality of life: reading acuity, speed (words per 
minute) and distance visual acuity (VA) are diminished (50, 52).  
 Diagnostic techniques used to identify the vasculature involved in uveitis are 
indocyanine green angiography (ICGA) and FA. ICGA is a water-soluble fluorescent 
molecule, intravenously injected and allows better visualisation of choroidal vasculature 
compared to FA that shows retinal vessels better. 
OCT in the course of uveitis is a superior diagnostic tool to determine any alteration at 
the vitreoretinal border, inflammation of the epiretinal membrane and most importantly uveitic 
macular edema (9, 50). 
 The first important step in the management of uveitis is the administration of anti-
inflammatory drugs in order to control the inflammation. They often lead to resolution of the 
edema in the case of nonischemic, nonatrophic macular edema. Therefore, oral and local 
steroids delivery are good first-choice agents but their use should be temporary because of the 
possible side effects. Newly developed systemic immunomodulators (i.e. biologic agents) 
show promising result for the control of inflammation (50). 
Unfortunately, anti-inflammatory drugs potency is not the same for every patient. For 
this reason, retinal pigmented epithelium (RPE) pump stimulator have been used to thwart the 
inflammatory effect with more or less conclusive result (50).   
Finally, well timed surgical intervention improves the vision and reduces injuries from 
previous inflammatory insults. Moreover, advanced UVE with vitreomacular traction can be 
managed by vitrectomy (50). 
 
 1.5.3. Postoperative cystoid macular edema 
 Postoperative cystoid macular edema (PCME) represents an abnormal accumulation of 
fluid in the macula and is responsible of blurred or distorted vision following operative 
procedures, such as: cataract surgery (known as Irvine-Gass syndrome), vitreoretinal surgery; 
and more severely after neodymium:yttrium-aluminum-garnet (Nd:YAG) capsulotomy, 
penetrating keratoplasty, scleral buckling, filtering procedures, and panretinal 
photocoagulation (53).  
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 CME etiology is not fully understood and remains hypothesis. The first hypothesis 
presents CME etiology as a macular prolapse caused by traction of the vitreous. The second, 
being the main theory, is based on the inherent inflammatory reaction triggered by surgical 
procedures that causes edema as a consequence of inflammatory mediators’ release (e.g. 
prostaglandins) (53). As explained above (cf. 1.2. Pathogenesis), the inflammation increases 
the permeability of the retinal layers by disrupting the blood-retinal barrier. 
 Chu et al. (54) reported a clinical CME incidence of 1.17-4.04% following modern 
cataract surgery performed by phacoemulsification. Angiographically proven CME is much 
more common with incidence ranging from 20% up to 70% depending on the studies (55). 
When considering CME diagnosed by optical coherence tomography (OCT) the incidence is 
between 4 and 10.9%. 
 Various risk factors promote the development of PCME and it is of upmost importance 
to identify them in order to prevent any visual alteration and provide the appropriate treatment. 
There are three main risks for CME to occur postoperatively: systemic factors, complicated 
surgery and previous ocular diseases. 
Systemic risk factors are principally diabetes mellitus and systemic hypertension. They 
both increase the incidence of PCME. 
Thanks to the introduction of new surgical procedures, such as phacoemulsification 
(cataract surgery), the PCME incidence have remarkably decreased and PCME is not anymore 
the principal consequence of intraoperative complications. However, surgical complications 
are still a recurrent risk increasing the likelihood of CME. 
Last but not least, pre-operative ocular conditions increase the risk for PCME, this 
includes: uveitis, diabetic retinopathy, retinal vein occlusion, etc. Interestingly, pre-operative 
drugs used in glaucoma patients increase the rate of CME (53). 
 Patients affected by PCME complain of visual symptoms (e.g. diminished visual acuity, 
eye redness, ocular irritation) mostly 4-12 weeks after the operation.  
On slit-lamp examination the most common sign of CME is a flattened fovea that is usually 
having a characteristic depressed appearance. However, biomicroscopy is not the most accurate 
diagnostic method as it misses 5-10% of the time CME. 
In consequence, more precise methods like FA or OCT are more commonly used in 
unsure PCME cases. OCT has the advantage to be noninvasive and able to quantify the 
evolution of the edema. Nonetheless, FA allows to define angiographic CME (i.e. leakage of 
fluorescein on FA examination of CME).  
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Thanks to the diagnostic techniques mentioned, PCME has been classified in 4 different 
degrees: acute (within 4 months postoperatively), late (more than 4 months postoperatively), 
chronic (more than 6 months postoperatively), and recurrent (53).  
 Interestingly, most of PCME cases resolve spontaneously with time. Zur et al. (53) have 
taken into consideration the newest available treatments and proposed, according to them, the 
best logical order for the management of PCME. Firstly, treatment of PCME with a 
combination of topical NSAIDs (e.g. ketorolac tromethamine, diclofenac or nepafenac) and 
topical steroids (i.e. prednisolone). Second-line treatment involves steroid (i.e. triamcinolone) 
sub-Tenon injection and intravitreal injection, with or without anti-VEGF agents, if the former 
is ineffective. At last, in the case of persistent inflammatory reaction, vitrectomy is advised. 
 
Therefore, the literature has not yet provided enough evidence regarding the results of 
pars plana vitrectomy (PPV) on non-existing and existing macular edema prior to surgery. 
Furthermore, there is a lack of information concerning the persistence of postoperative macular 
edema after pars plana vitrectomy. All of that reinforces our idea to conduct the necessary 
investigations to help answer these incertitudes.  
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2. OBJECTIVES 
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AIMS: 
1. Determine the impact of pars plana vitrectomy on the evolution of pre-existing and non-
existing macular edema. 
2. Determine the quantitative persistence of macular edema postoperatively throughout 
time. 
 
HYPOTHESIS: 
1. The macular thickness of non-existing macular edema prior to surgery will be 
significantly increased after PPV.  
2. The macular thickness of existing macular edema prior to surgery will be significantly 
decreased after PPV. 
3. Delayed postoperative macular edema will persist over time.  
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3. MATERIALS AND METHODS 
 
 
17 
3.1. Ethical background of data collection  
 
 All data used for this thesis was obtained at the Ophthalmology outpatient department 
of University Hospital of Split, and was approved by the Ethics Committee of University 
Hospital of Split.  
 
3.2. Study purpose 
 
 On the basis of findings, from a study reviewing patients affected by macular edema 
after surgical interventions of the eye (53), the decision was made to conduct the study. 
The purpose of the study was to evaluate the impact of pars plana vitrectomy on non-
existing and pre-existing macular edema prior to surgery, and to assess the persistence of 
macular edema after PPV will the help of OCT.  
   
3.3. Subjects 
 
 The retrospective study included 91 eyes in 91 patients, with 51 right eyes and 40 left 
eyes, for 30 women and 61 men who were affected by postoperative cystoid macular edema. 
Participants were middle to older aged adults, ranging from 32-85 years with an average patient 
age of 68,5 years. 
 Data were collected from the 10th of February 2015 until the 16th of November 2018. 
Data have been systemized and analysed from the 26th of March 2018 until the 1st of June 2018. 
All patients included in the study have had pars plana vitrectomy (PPV). 
  
3.4. Methods 
 
Ninety-one patients were included in the study and has many eyes underwent pars plana 
vitrectomy. No preoperative treatment was intended in any of the patients. Postoperative 
treatment has been the same for all the 91 patients: topical eye drops composed of a 
combination of steroids (dexamethasone) and antibiotics (neomycin and polymyxin b) that 
were administered 3 to 4 times per day for 3 weeks. 
The data were collected with a Zeiss Cirrus HD-OCT (Cirrus version 6.1 software) and 
macular cube 512 × 128 protocol.  
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Preoperative OCT results were gathered within 1 month to 1 year prior to surgery.  In 
addition, the 1st, 2nd and 3rd OCT postoperative check-up were collected approximately a week, 
a month, and 3 months postoperatively. Spectral domain optical coherence tomography (SD-
OCT) measurements included four main information about the macula: central subfield 
thickness (CST), cube volume (CV), cube average thickness (CAT), and macular foveal 
thickness (MFT). The latter, have been manually measured for each patient OCT scan. The 
measure was performed from the retinal pigmented membrane until the foveal groove at the 
fovea centralis (Figure 6). A MFT value superior to 220 µm was considered as the threshold 
for macular edema (56). 
 
 
 
Figure 6. The retinal architecture of a healthy eye on OCT scan. 
 
The study outcome measures were CST, CV, CAT and MFT. The Early Treatment 
Diabetic Retinopathy Study (ETDRS) has defined clinical significant macular edema (CSME) 
and divided the macula into nine different areas (Figure 7) (34). The SD-OCT automatically 
calculates: CST as the mean thickness of the central circle that is 1 mm in diameter and is 
expressed in µm; CV as the sum of all nine retinal regions volume, normal CV is 6mm x 6mm 
and is expressed in mm3; CAT is the macular cube average thicknesses of the retina, measured 
NFL: Nerve fiber layer 
ILM: Inner limiting membrane 
GCL: Ganglion cell layer 
IPL: Inner plexiform layer 
INL: Inner nuclear layer 
OPL: Outer plexiform layer 
ONL: Outer nuclear layer 
ELM: External limiting membrane 
IS: Photoreceptor inner segment 
OS: Photoreceptor outer segment 
IS/OS: Interface between IS and    
            OS 
RPE: Retinal pigment epithelium 
OPR: Outer photoreceptor/ RPE        
          complex 
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from the ILM to the RPE, and expressed in µm; MFT is the mean macular foveal thickness 
and, as mentioned above, is measured manually and expressed in µm (Figure 8).  
 
 
Figure 7. ETDRS areas of the macula as measured by fast macula program of OCT (57). 
 
 
 
 
 
 
 
 
 
 
Figure 8. Macular foveal thickness (MFT), central subfield thickness (CST), cube average 
thickness (CAT) and cube volume (CV) representation of the macula. 
 
 
 
CAT 
CV 
CST MFT 
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3.5. Statistical methods 
 
Statistical analysis was performed using the statistical software Statistica 12 (StatSoft 
Inc., Tulsa, OK, USA) applying Chi square test and Wilcoxon matched pairs test. Chi square 
test was performed to measure the differences existing in the sample. Wilcoxon mactched pairs 
test was used to analyse the impact of surgery on macular thickness and the persistence of 
macular edema over time. The statistical significance value was set at P˂0.05. 
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4. RESULTS 
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4.1. Baseline Characteristics  
 
The retrospective study included 91 eyes in 91 patients, with 51 right eyes (56 %) and 
40 left eyes (44%), for 30 women (33%) and 61 men (67%) who were affected by postoperative 
cystoid macular edema. Participants were middle to older aged adults, ranging from 32-85 
years with an average patient age of 68,5 years (CI 65-71) (Table 1). 
There was statistical significant difference in between the number of men and women 
involved in the study, with a majority of men 67% (P=0.001). On the other hand, no statistical 
significant difference was observed in between the left and the right eyes (P=0.249). 
In preoperative database, 55 patients out of 91 patients included in the study have had 
a preoperative optic coherence tomography (OCT) recording (60.4% of total sample). In 
postoperative database, 76 patients have had a single postoperative OCT recording (83.5% of 
total sample); 35 patients have had a second postoperative OCT recording (38.5% of total 
sample); 15 patients have had a third postoperative OCT recording (16.5% of total sample). 
 
 
       Table 1. Demographic data 
 
Characteristic   N (%)     P* 
Gender      0.001 
   Male  61 (67)   
     Female  30 (33) 
Eye      0.249 
   Right  51 (56)   
     Left  40 (44) 
Preoperative OCT  55 (60,4)   
Postoperative OCT       
  1 76 (83.5)   
  2 35 (38.5)   
  3 15 (16.5)   
  4 6 (6.6)   
  5 4 (4.4)   
  6 2 (2.2)   
  7 1 (1.1)   
       Data are presented as median or as general number (%)  
       *empirical p value of Chi square test 
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The results for 37 of the 91 eyes were excluded from the study because of absent 
preoperative OCT measures. Indeed, preoperative OCT data are not possible to be obtain in 
patients affected by certain eye conditions, such as: haemophthalmus, retinal detachments, 
severe vitreous opacities, etc. Additionally, the results for 14 eyes were not included because 
of the absence of the first postoperative OCT scan. Consequently, 51 eyes were excluded from 
the study and 40 eyes having both preoperative and first postoperative OCT check-up were 
able to be compared. Among the 40 eyes, 6 had non-existing macular edema preoperatively 
and the rest were considered has pre-existing preoperative macular edema (i.e. 34 eyes). 
Complete OCT data on the 2nd check-up were available for 35 eyes as 5 participants dropped 
out from the study (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Study flow chart. PreOp = preoperative OCT; PostOp1 = 1st postoperative OCT; 
PostOp2 = 2nd postoperative OCT; PostOp3 = 3rd postoperative OCT. 
 
 
 
37 absent preoperative OCT 
91 participants 
54 eyes 
40 included eyes for 
PreOp/PostOp1 OCT analysis 14 absent postoperative OCT1 
35 included eyes for 
PostOp1/PostOp2 OCT analysis 5 absent postoperative OCT2 
15 included eyes for 
PostOp2/PostOp3 OCT analysis 20 absent postoperative OCT3 
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4.2. Study Outcome 
 
SD-OCT measurements included four main information about the macula: central 
subfield thickness (CST), cube volume (CV), cube average thickness (CAT), and macular 
foveal thickness (MFT in µm). MFT have been manually measured for each patient OCT scan. 
The measure was performed from the retinal pigmented membrane until the foveal groove at 
the fovea centralis. 
 
4.2.1. Preoperative and first postoperative OCT recordings comparison 
There was significant difference in between preoperative macular thickness compared 
to postoperative macular thickness. CST, CV, CAT and MFT were significantly decreased on 
first optical coherence tomography (OCT1) (P=0.004, P=0.016, P=0.026, P=0.047). CST, CV, 
CAT and MFT measurements were compared for 40 matched pairs eyes (Table 2). 
 
Table 2. Preoperative and postoperative 1 OCT data comparison 
Parameters Preoperative OCT Postoperative OCT1 Differences 
  Median (IQR) Median (IQR) Z P* 
 
CST 
 
CV 
 
344 (264-468) 
 
11 (10-13) 
297 (244-352) 
 
11 (10-12) 
2.91 
 
2.40 
0.004 
 
0.016 
CAT 
 
MFT 
300 (279-341) 
 
325 (230-444) 
295 (281-324) 
 
239 (188-362) 
2.22 
 
1.98 
0.026 
 
0.047 
Data are presented as median with interquartile range. 
* Wilcoxon Matched Pairs Test 
 
 There was significant difference in between preoperative OCT data compared to OCT1 
in patients with existing macular edema prior to PPV. Indeed, CST, CV, CAT and MFT have 
significantly been decreased on 1st postoperative visit (P=0.002; P=0.007; P=0.008; P=0.026). 
Preoperative macular edema and its postoperative evolution has been compared thanks to CST, 
CV, CAT and MFT in 34 matched pairs eyes with pre-existing macular edema (MFT>220 µm) 
(Table 3).  
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On the other hand, there was no significant difference in between the macular thickness 
preoperative OCT measurements compared to postoperative OCT 1 in patients without macular 
edema prior to surgery. CST, CV, CAT and MFT were analysed in 6 matched pairs eyes with 
non-existing macular edema before PPV (MFT≤220 µm) (Table 4). 
 
Table 3. Preoperative and first postoperative OCT data comparison in 34 patients affected by        
               macular edema prior to PPV. 
Parameters Preoperative  Postoperative OCT1 Differences 
  Median (IQR) Median (IQR) Z P* 
 
CST 
 
CV 
 
389 (338-496) 
 
11.7 (10.7-13.8) 
323 (286-431) 
 
10.9 (10.4-12.2) 
3.06 
 
2.66 
0.002 
 
0.007 
CAT 
 
MFT 
325 (298-384) 
 
378 (311-460) 
304 (290-338) 
 
344 (241-467) 
2.64 
 
2.22 
0.008 
 
0.026 
Data are presented as median with interquartile range. 
* Wilcoxon Matched Pairs Test 
 
Table 4. Preoperative and postoperative OCT data comparison in 6 patients not affected by 
macular edema prior to PPV 
Parameters Preoperative OCT Postoperative OCT1 Differences 
  Median (IQR) Median (IQR) P* 
 
CST 
 
CV 
 
256 (242-305) 
 
10.3 (10-10.5) 
268 (224-350) 
 
10.4 (10.2-12.2) 
1.000 
 
0.625 
CAT 
 
MFT 
286 (279-290) 
 
189 (170-201) 
288 (282-338) 
 
203 (148-276) 
0.563 
 
0.463 
Data are presented as median with interquartile range. 
* Wilcoxon Matched Pairs Test 
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4.2.2. First postoperative and second postoperative OCT follow-up comparison  
 
There was significant difference in between the macular thickness in the first 
postoperative OCT (OCT1) compared to the second postoperative OCT (OCT2). CAT and 
MFT were significantly increased on OCT2 follow-up (P=0.019, P=0.015) while CV stayed 
the same. However, there was no significant difference in CST after the second OCT 
(P=0.130). Five patients did not have OCT2, thus, the comparison has included 35 matched 
pairs eyes (Table 5). 
 
Table 5. Postoperative 1 and postoperative 2 OCT recordings comparison 
Parameters Postoperative 1 Postoperative 2 Differences 
  Median (IQR) Median (IQR) Z P* 
 
CST 
 
CV 
 
297 (244-352) 
 
11 (10-12) 
329 (271-415) 
 
11 (10-12) 
1.51 
 
2.35 
0.130 
 
0.019 
CAT 
 
MFT 
295 (281-324) 
 
239 (188-362) 
301 (276-326) 
 
313 (201-410) 
2.35 
 
2.44 
0.019 
 
0.015 
Data are presented as median with interquartile range. 
* Wilcoxon Matched Pairs Test 
 
 
 4.2.3. Second postoperative and third postoperative OCT follow-up comparison 
 There was significant difference in between postoperative OCT2 macular thickness 
compared to postoperative OCT 3 (OCT3) macular thickness. CST, CV and MFT were 
significantly decreased on OCT3 (P=0.020, P=0.017, P=0.013). Nevertheless, CAT has shown 
no significant difference in between postoperative OCT2 and OCT3 follow-up (P=0.389). 
Since twenty patients did not have OCT3, 15 matched pairs eyes were compared on the third 
check-up (Table 6). 
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Table 6. Postoperative 2 and postoperative 3 OCT recordings comparison 
 
Parameters Postoperative 2 Postoperative 3 Differences 
  Median (IQR) Median (IQR) P* 
 
CST 
 
CV 
 
301 (285.5-335) 
 
10.8 (10.3-12.1) 
292 (277-320) 
 
10.5 (10-11.5) 
0.020 
 
0.017 
CAT 
 
MFT 
369 (274-463) 
 
319 (225-504) 
325 (259-393) 
 
319 (210-377) 
0.389 
 
0.013 
Data are presented as median with interquartile range. 
* Wilcoxon Matched Pairs Test 
 
 4.2.4. Summary of study outcome 
 At study conclusion, it is interesting to note that macular edema has been influenced by 
pars plana vitrectomy, the Figure 10, 11 and to a lesser extent Figure 12 are representative of 
the impact of surgery. Furthermore, postoperative discrepancy of the different OCT data 
collected illustrate well the difficulty to get rid of macular edema. 
 
 
     Figure 10. Average macular foveal thickness (MFT) (µm) in all included patients at    
     different OCT follow-up. OCT = preoperative OCT; OCT1 = postoperative OCT1; OCT2          
     = postoperative OCT2. OCT3 = postoperative OCT3. 
325
239
313
319
200
220
240
260
280
300
320
340
OCT OCT1 OCT2 OCT3
M
ac
ul
ar
	fo
ve
al
	th
ick
ne
ss
	(µ
m
)
 
 
28 
 
Figure 11. Average central subfield thickness (CST) (µm) in all included patients at 
different OCT follow-up. OCT = preoperative OCT; OCT1 = postoperative OCT1; OCT2 
= postoperative OCT2. OCT3 = postoperative OCT3. 
 
 
 
Figure 12. Median cube average thickness (CAT) (µm) in all included patients at 
different OCT follow-up. OCT = preoperative OCT; OCT1 = postoperative OCT1; OCT2 
= postoperative OCT2. OCT3 = postoperative OCT3. 
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Figure 13. Average cube volume (CV) (mm3) in all included patients at different OCT 
follow-up. OCT = preoperative OCT; OCT1 = postoperative OCT1; OCT2 = 
postoperative OCT2. OCT3 = postoperative OCT3. 
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5. DISCUSSION 
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Macular edema (ME) knock-on effect is triggered by the accumulation of fluid, which 
leads to an alteration of the retinal architecture and consequently to loss of vision. The 
expansion of fluid in the macula begins in the outer plexiform layer and extend towards the 
inner nuclear and inner plexiform layers of the retina (Figure 1 and 2). The thickening of the 
central portion of the macula around the fovea characterizes macular edema (1).  
The diagnosis of macular edema has been possible thanks to distinct observational 
methods. On the basis of detecting postsurgical macular edema, optical coherence tomography 
(OCT) is of upmost accuracy (53). OCT use allowed us to evaluate the impact of pars plana 
vitrectomy (PPV) on macular edema and its persistence over time. 
Macular edema is a slow, fluctuating process and can be caused by different eye 
conditions, such as: diabetic retinopathy, retinal vein occlusion, uveitis, intraocular surgery, 
etc. (1) For this reason, a multitude of treatment strategies have been implemented in order to 
reduce and solve macular edema (15). 
Our study aimed to determine the impact and persistence of macular edema after pars 
plana vitrectomy.  
 In this study, we have found that macular thickness (MT), represented by macular 
foveal thickness (MFT), central subfield thickness (CST), cube average thickness (CAT) and  
cube volume (CV), was significantly reduced on OCT after pars plana vitrectomy (Table 2). 
The results tended to be similar when we only considered preoperative participants (34 eyes) 
with existing macular edema prior to surgery (Table 3). In view of our results, it seems that 
PPV helps to decrease pre-existing macular edema (Table 2 and 3). 
Our study results are supported by different theories in the literature. Firstly, in the case 
of vitreomacular traction, PPV releases the traction pressure which leads to reduced blood 
vessels leakage into the retinal tissue (58). Secondly, in the case of macular edema of vascular 
origin (e.g. diabetic retinopathy and retinal vein occlusion), vitrectomy has been proven to 
increase the transport of oxygen in the eye and to remove excessive inflammatory growth 
factors, thus decreasing macular edema (58). Finally, peeling of the internal limiting membrane 
performed seems to be another beneficial effect of PPV for reducing macular edema (59). 
 Depending on the analysed mean, the evolution of postoperative macular edema, in our 
study, is not following the same pattern throughout time. Indeed, MFT, CST and CAT are 
increased in between OCT follow-up one (OCT1) and two (OCT2), unlike CV that stayed 
constant. On the other hand, when comparing OCT follow-up two and three (OCT3): CST and 
CV are decreased but most importantly, MFT is constant or slightly increased and CAT is 
increased (Figure 10,11,12 and 13). Therefore, along OCT check-ups, the evolution of post-
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pars plana vitrectomy macular edema tend to be persistent over time and to follow the same 
pattern as post-cataract surgery macular edema. Accordingly, postsurgical macular edema 
seems to not only be a long-term complication of cataract surgery but as well a long-term 
complication of pars plana vitrectomy. We can suppose, following the last sentence 
assumption, that most post-PPV macular edema cases resolve spontaneously after a certain 
time with only a small percentage reaching clinical relevance (53). 
 For further investigations of recalcitrant macular edema after vitreoretinal surgery, it 
would be first interesting to include a bigger number of participants and includes more subjects 
with non-existing macular edema prior to surgery. Secondly, preoperative and postoperative 
OCT follow-ups should be scheduled at regular time intervals for all participants (e.g. within a 
month preoperatively, at 4 months, 6 months and a year postoperatively). Furthermore, 
participants should as well be evaluated according to the condition that caused them the 
necessity to have vitrectomy. Moreover, macular foveal thickness should be measured 
manually by an ophthalmologist that is experienced in the use and interpretation of optical 
coherence tomography in order to limit the bias inherent to this process. Finally, OCT scans 
that yielded poor image quality and scans with signal strength below 5 should be disregarded 
for better analysis of OCT measurements (MFT, CST, CAT, CV). 
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6. CONCLUSIONS 
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1. The macular thickness of non-existing macular edema prior to surgery has not be 
significantly increased after pars plana vitrectomy (PPV).  
2. Macular thickness of existing macular edema prior to surgery was significantly 
decreased after PPV.  
3. Macular edema after vitreoretinal surgery has a tendence to develop not immediately 
after surgery and to persist in time if not timely recognized and properly treated. 
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8. SUMMARY 
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A RETROSPECTIVE STUDY OF RECALCITRANT MACULAR EDEMA 
FOLLOWING VITREORETINAL SURGERY 
 
Objectives: Macular edema describes the slow and fluctuating accumulation of fluid in the 
central portion of the retina around the fovea. Intraocular surgery and other different eye 
conditions can trigger this process. Our study was aimed to determine the impact and 
persistence of macular edema after pars plana vitrectomy.  
 
Materials and methods: A retrospective study was carried out on 91 eyes in 91 patients with 
past scheduled history of pars plana vitrectomy (PPV) and an age range of 31 to 85 (mean 68.5) 
years. Spectral domain optical coherence tomography (SD-OCT) imaging was performed to 
evaluate macular thickness, including measurements of central subfield thickness (CST), cube 
volume (CV), cube average thickness (CAT) and manual measurement of macular foveal 
thickness (MFT).   
 
Results: There was significant difference of macular thickness in between preoperative OCT 
and postoperative OCT1 follow-ups in 40 included patients. Indeed, CST, CV, CAT and MFT 
were significantly decreased on postoperative OCT1 (P=0.004, P=0.016, P=0.026, P=0.047). 
Similarly, macular thickness was significantly decreased postoperatively (OCT1) in patients 
with existing macular edema prior to surgery (n=34), with OCT measurements (CST, CV, CAT 
and MFT) significantly decreased on OCT1 (P=0.002; P=0.007; P=0.008; P=0.026). 
Postoperative macular foveal thickness was significantly increased in between OCT1 and 
OCT2 (n=35) and in between OCT2 and OCT3 (n=15) follow-ups (P=0.015, P=0.013). 
 
Conclusion: The macular thickness of non-existing macular edema prior to surgery has not be 
significantly increased after (PPV). However, macular thickness of existing macular edema 
prior to surgery was significantly decreased after PPV. Finally, macular edema after 
vitreoretinal surgery is still present after the third optical coherence tomography follow-up 
(approximately 3 months postoperatively). 
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9. CROATIAN SUMMARY  
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Naslov: RETROSPEKTIVNA STUDIJA PERZISTENTNOG MAKULARNOG 
EDEMA NAKON VITREORETINALNE KIRURGIJE 
 
Ciljevi:  
Makularni edem predstavlja sporo nastajuće i fluktuirajuće nakupljanje tekućine u centralnom 
dijelu mrežnice oko fovee. Intraokularna kirurgija i druge očne bolesti mogu pokrenuti ovaj 
proces. Naša studija je imala za cilj istražiti učestalost i klinički tijek makularnog edema 
uzrokovanog pars plana vitrekromijom 
 
Materijali i metode:  
Studija je provedena retrospektivno na 91 oku 91 pacijenta koji su bili podvrgnuti pars plana 
vitrektomiji (PPV). Uključeni bolesnici su bili u rasponu od 31 do 85 godina starosti (srednja 
vrijednost 68,5 godina). Optička koherentna tomografija spektralne domene (engl. Spectral 
Domain Oprical Coherence Tomography – SD-OCT) je bila snimana kako bi se procijenila 
debljina makule, uključujući mjere kao što su CST (engl. Central subfield thickness), CV (engl. 
Cube volume), CAT (engl. Cube avarage thisckess) te je bila manualno izmjerena debljina 
fovee (engl. Macular foveal thickness – MFT). 
 
Rezultati: 
U 40 praćenih bolesnika nađeno je značajno smanjenje debljine makule zabilježene prilikom 
preoperativnog OCTa i prvog postoperativnog OCTa. Naime, CST, CV, CAT i MFT su bili 
značajno smanjeni na prvom postoperativnom OCTu (P=0,004; P=0,016; P=0,026; P=0,047). 
Također, makularna debljina je bila značajno smanjena na prvom opostoperativnom OCTu u 
bolesnika s prisutnim predoperativnim makularnim edemom (n=34). Kod tih bolesnika CST, 
CV, CAT i MFT su bili značajno niži (P=0,002; P=0,007; P=0,008; P=0,026). Makularna 
fovealna debljina postoperativno je bila značajno veća između OCT1 i OCT2 (n=35) i između 
OCT2 i OCT3 (n=15) (P=0,015; P=0,013). 
 
Zaključak:  
Debljina makule nije bila značajno povećana nakon PPVa u odnosu na preoperativne 
vrijednosti. Također smo zabilježili da se makularni edem, koji je bio prisutan prije operacije, 
značajno smanjio nakon PPVa. Na koncu je zabilježeno da se postoperativni makularni edem 
zadržava i nakon treće postoperativne kontrole (aproksimativno 3 mjeseca nakon operacije). 
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